Marco Rossi
Marco Rossi
University Magna Graecia-Catanzaro-Italy
Email verificata su
Citata da
Citata da
Role of nucleophosmin in embryonic development and tumorigenesis
S Grisendi, R Bernardi, M Rossi, K Cheng, L Khandker, K Manova, ...
Nature 437 (7055), 147-153, 2005
Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity
M Rossi, JW Young
The Journal of Immunology 175 (3), 1373-1381, 2005
Indoleamine 2, 3-dioxygenase–expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells
DJ Chung, M Rossi, E Romano, J Ghith, J Yuan, DH Munn, JW Young
Blood, The Journal of the American Society of Hematology 114 (3), 555-563, 2009
Synthetic miR-34a mimics as a novel therapeutic agent for Multiple Myeloma: in vitro and in vivo evidence
MT Di Martino, E Leone, N Amodio, U Foresta, M Lionetti, MR Pitari, ...
Clinical cancer research 18 (22), 6260-6270, 2012
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth
E Leone, E Morelli, MT Di Martino, N Amodio, U Foresta, A GullÓ, M Rossi, ...
Clinical Cancer Research 19 (8), 2096-2106, 2013
miR‐29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma‐related bone disease
M Rossi, MR Pitari, N Amodio, MT Di Martino, F Conforti, E Leone, C Botta, ...
Journal of Cellular Physiology, 2012
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1
N Amodio, MT Di Martino, U Foresta, E Leone, M Lionetti, M Leotta, ...
Cell death & disease 3 (11), e436, 2012
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials
D Ciliberto, C Botta, P Correale, M Rossi, M Caraglia, P Tassone, ...
European journal of cancer 49 (3), 593-603, 2013
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma
S Blotta, J Jakubikova, T Calimeri, AM Roccaro, N Amodio, AK Azab, ...
Blood, The Journal of the American Society of Hematology 120 (25), 5002-5013, 2012
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies
N Amodio, M Rossi, L Raimondi, MR Pitari, C Botta, P Tagliaferri, ...
Oncotarget 6 (15), 12837, 2015
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells
T Calimeri, E Battista, F Conforti, P Neri, MT Di Martino, M Rossi, ...
Leukemia 25 (4), 707-711, 2011
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo
E Morelli, E Leone, ME Cantafio, MT Di Martino, N Amodio, L Biamonte, ...
Leukemia 29 (11), 2173-2183, 2015
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts
MR Pitari, M Rossi, N Amodio, C Botta, E Morelli, C Federico, A GullÓ, ...
Oncotarget 6 (29), 27343, 2015
miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells
N Amodio, D Bellizzi, M Leotta, L Raimondi, L Biamonte, P D’Aquila, ...
Cell Cycle 12 (23), 3650-3662, 2013
In Vitro and In Vivo Activity of a Novel Locked Nucleic Acid (LNA)-Inhibitor-miR-221 against Multiple Myeloma Cells
MT Di Martino, A GullÓ, ME Gallo Cantafio, E Altomare, N Amodio, ...
PloS one 9 (2), e89659, 2014
Promises and challenges of MicroRNA-based treatment of multiple myeloma
P Tagliaferri, M Rossi, M T Di Martino, N Amodio, E Leone, A Gulla, A Neri, ...
Current cancer drug targets 12 (7), 838-846, 2012
Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation In Vitro, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loadedá…
E Romano, M Rossi, G Ratzinger, MA de Cos, DJ Chung, KS Panageas, ...
Clinical Cancer Research 17 (7), 1984-1997, 2011
In vivo anti‐myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor
P Neri, P Tagliaferri, MT Di Martino, T Calimeri, N Amodio, A Bulotta, ...
British journal of haematology 143 (4), 520-531, 2008
Molecular targets for the treatment of multiple myeloma
M Rossi, M Teresa Di Martino, E Morelli, M Leotta, A Rizzo, A Grimaldi, ...
Current cancer drug targets 12 (7), 757-767, 2012
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patientsá…
MT Di Martino, M Arbitrio, PH Guzzi, E Leone, F Baudi, E Piro, T Prantera, ...
British journal of haematology 154 (4), 529, 2011
Il sistema al momento non pu˛ eseguire l'operazione. Riprova pi¨ tardi.
Articoli 1–20